Rockin Robin SongFlying The Web For News.
RobinsPost Logo RobinsPost Amazon





Globe NewsWire News Distribution Service


Geneva, Switzerland and Westport, CT, Nov. 18, 2019 (GLOBE NEWSWIRE) -- Launched today, the Alliance for Advancing Bioelectronic Medicine (AABM) is an independent network of professionals united to advance bioelectronic medicine – one of the most innovative and exciting fields in healthcare. The alliance aims to align bioelectronic medicine leaders on shared goals, facilitate cross-sector collaboration, mobilize key external audiences, and build awareness of the field overall.

“Bioelectronic medicine represents a tremendous opportunity to improve patients’ lives and change our world. However, achieving this will require much greater collaboration and awareness from a much larger and more diverse group of stakeholders,” said Kenneth L. Londoner, Founder, CEO, and Chairman of BioSig Technologies, a medical technology company that has supported creation of AABM. “We believe that the Alliance for Advancing Bioelectronic Medicine will play a much-needed role by aligning and amplifying voices in the field, winning over new allies, and driving progress that, ultimately, benefits everyone.”

The alliance brings together leaders in bioelectronic medicine: a rapidly growing field of healthcare that explores how targeted electrical signals can harness the body’s natural mechanisms to diagnose and treat a range of diseases. Its members are committed to realizing the potential of bioelectronic medicine to transform diagnosis and care for millions of people, particularly in areas of unmet need such as Parkinson’s disease, major depressive disorder, treatment-resistant epilepsy, heart arrhythmia, and chronic pain.

“The Alliance for Advancing Bioelectronic Medicine will support greater collaboration among experts across different sectors, disease areas, disciplines, and specialties,” said Samuel Asirvatham, M.D. a founding member of AABM and Vice Chair, Innovation and Medical Director, Electrophysiology Laboratory, Cardiovascular Diseases at the Mayo Clinic. “The collaboration hopes to pave the way to novel diagnostics and treatment options for patients.”

 The alliance grew out of an invitation-only roundtable in the spring of 2019, at which a distinguished group of researchers, entrepreneurs, and healthcare experts agreed on the need for an ongoing dialogue to advance a shared vision for bioelectronic medicine and a catalyst to unite the field. Since that gathering, members have developed a consensus on a shared definition, a unified narrative, and a set of tailored messages for the many groups that stand to benefit from bioelectronic medicine.

“We’ve seen impressive scientific and medical progress in bioelectronic medicine in recent years,” said Dr. Hein Heidbuchel, Professor and Chair of Cardiology, Antwerp University and President of the European Heart Rhythm Association. “But what has been missing is a compelling story that builds understanding and support for this field across a wide range of relevant audiences.”

The Alliance for Advancing Bioelectronic Medicine aims to play a unique convening role, mobilizing patients, physicians, and other stakeholders to advocate for the field, and increasing awareness among audiences that are important for the field’s growth, including policymakers, investors, media, and the general public. Its steering committee includes experts with experience at Battelle, European Heart Rhythm Association, The Feinstein Institute, Heart Rhythm Society, Imperial College London, Mayo Clinic, RAND Corporation and Sheba Medical Center. 

The alliance will be coordinated by High Lantern Group, a strategic positioning firm active in global health policy. “We see great potential for bioelectronic medicine to help serve unmet medical needs and achieve healthier societies,” said Mario Ottiglio, Managing Director at High Lantern Group. “We look forward to collaborating with this community to shape a compelling policy agenda that attracts broad support and helps accelerate the growth of this nascent industry.”

For more information, please contact:

Ms. Julie Pierce

Managing Director

High Lantern Group 

Ms. Natasha Drapeau

Executive Vice President

BioSig Technologies, Inc.


This email address is being protected from spambots. You need JavaScript enabled to view it.

+1 203-409-5444, x119  

Meryl Ellingson
High Lantern Group
6263442722
This email address is being protected from spambots. You need JavaScript enabled to view it.


Posted: 2019-11-18 23:41:00

Get Full News Story On GlobeNewsWire Press Release Service


Listen to this article. Speaker link opens in a new window.
Text To Speech BETA Test Version.



More News From This Category
Press Release: RadiantVibe Capital Consortium Debuts Insight Access Dashboard as Part of Ambrose Wetherby’s Transparency Initiative
Sat, 06 Dec 2025 17:07:24 +0000

New York, NY, Dec. 06, 2025 (GLOBE NEWSWIRE) -- RadiantVibe Capital Consortium today announced the debut of its new Insight Access Dashboard, a centralized interface designed to improve information accessibility and strengthen organizational transparency. The launch marks a key milestone in founder Ambrose Wetherby’s Transparency Initiative, a long-term effort to enhance clarity, structure, and consistency…

Read More ...


Press Release: MAREX URGENT DEADLINE REMINDER: Bragar Eagel & Squire, P.C. Urges Marex Stockholders to Contact the Firm Before December 8th Deadline
Sat, 06 Dec 2025 14:07:27 +0000

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Marex (MRX) To Contact Him Directly To Discuss Their Options If you purchased or acquired Marex securities between May 16, 2024 and August 5, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Melissa Fortunato…

Read More ...


Press Release: Sapu Nano 公布新的药代动力学数据显示,与口服给药相比,静脉注射 Sapu003 可将依维莫司的胃肠道积累量减少 67 倍
Sat, 06 Dec 2025 11:07:36 +0000

加利福尼亚州圣迭戈, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Sapu Nano 今日公布了最新的药代动力学 (PK) 和组织分布研究结果,证实基于该公司 Deciparticle™ 专利技术的依维莫司静脉注射 (IV) 制剂 Sapu003 可显著减少药物在胃肠道的蓄积,从而解决了口服依维莫司(Afinitor®)最显著且广为人知的局限性之一。  数据显示,Sapu003 能提供更高的耐受性,同时保留该药物固有的代谢特性,并能提升不同患者之间全身暴露量的一致性。

Read More ...


Press Release: Scatec starts commercial operation at Grootfontein solar power plant in South Africa
Sat, 06 Dec 2025 08:07:40 +0000

Oslo/Cape Town, 06 December 2025: Scatec ASA, a leading renewable energy provider, has started commercial operation of the 273 MW Grootfontein solar power plant in South Africa, which will generate predictable revenues from a 20-year power purchase agreement (PPA).

Read More ...


Press Release: FCX INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Freeport McMoRan Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit
Sat, 06 Dec 2025 05:07:43 +0000

SAN DIEGO, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Freeport-McMoRan Inc. (NYSE: FCX) publicly traded securities between February 15, 2022 and September 24, 2025, inclusive (the “Class Period”), have until Monday, January 12, 2026 to seek appointment as lead plaintiff of the Freeport-McMoRan class…

Read More ...


Related Bing News Results





















Blow Us A Whistle


Related Product Search/Búsqueda de productos relacionados

Amazon Logo